LGMN and triple-A syndrome: Combining ROC analysis and literature retrieval results, Legumain (LGMN) was selected as the key protein that could serve as a novel diagnostic biomarker of AAA, with an AUC of 0.893 (95% CI: 0.739–0.986, p < 0.001) (Figure 2A).